Intensity Therapeutics Inc
Research Intensity Therapeutics Inc (INTS) on Bullrun: market cap USD 9.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerINTS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.75M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.01M
- Free cash flow-USD 2.34M
Valuation Snapshot
latest market cap is USD 9.75M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 11.61M | -USD 9.23M | n/a | -8.56 | USD 11.92M | USD 110.00K | USD 11.88M |
| FY2024 | USD 0 | -USD 16.27M | -USD 15.22M | n/a | -29.24 | USD 2.59M | USD 138.00K | USD 2.92M |
| FY2023 | USD 0 | -USD 10.54M | -USD 7.21M | n/a | -1.38 | USD 8.56M | USD 158.00K | USD 13.16M |
| FY2022 | USD 0 | -USD 7.58M | -USD 5.48M | n/a | -2.22 | USD 1.31M | USD 4.49M | -USD 15.10M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 9.75M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 615.67M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 665.41M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.94B | n/a | n/a | n/a |
About Intensity Therapeutics Inc
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Intensity Therapeutics Inc's market cap?
Intensity Therapeutics Inc's market capitalization is USD 9.75M.
What does Intensity Therapeutics Inc do?
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.